Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 40,807	$ 54,951
Marketable securities, available-for-sale	325,984	283,554
Accounts receivable from government grants, net	108	417
Prepaid expenses and other current assets	10,423	6,182
Restricted cash	243	0
Total current assets	377,565	345,104
Property and equipment, net	4,698	1,099
Operating lease right-of-use assets	693	2,520
Prepaid expenses and other assets	6,042	2,976
Goodwill	3,736	3,736
In-process research and development	0	8,800
Investment in Zentera Therapeutics	39,326	0
Restricted cash	3,021	1,320
Total assets	435,081	365,555
Current liabilities
Accounts payable	8,046	8,661
Accrued expenses	31,369	19,940
Total current liabilities	39,415	28,601
Deferred tax liability	1,670	2,480
Other long-term liabilities	0	1,097
Total liabilities	41,085	32,178
Commitments and contingencies
EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized; 45,198,528 and 41,040,286 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	45	41
Additional paid-in capital	702,855	509,339
Accumulated other comprehensive income	32	36
Accumulated deficit	(309,500)	(200,834)
Total stockholders’ equity	393,432	308,582
Noncontrolling interests	564	24,795
Total equity	393,996	333,377
Total liabilities and stockholders’ equity	$ 435,081	$ 365,555